A trio of researchers are suggesting in a Comment piece in the journal Nature, that the FDA should cease regulating fecal transplants as drugs and should instead begin treating them as tissue product procedures. In their article, Mark Smith, Colleen Kelly and Eric Alm suggest that treating fecal material as a drug is inhibiting research into its beneficial possibilities and is preventing its use in many instances by physicians unwilling to undergo the bureaucratic process needed with unapproved drugs.First Fecal Transplant Bank Opens
The Massachusetts-based company has delivered stool samples to 13 hospitals around the country.Bacteria Help Make Healthy Sausages
This is serious science, but scatological humor seems to be irresistible.
